Mitsubishi Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Higashi-Yoshitomi-mura Japan (1921)
Status: Acquired by Mitsubishi Tanabe (1999)

Organization Overview

First Clinical Trial
2005
NCT00508924
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Information at Mitsubishi Pharma America | Information at Mitsubishi Pharma Europe | Mitsubishi Logistics Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina, Unstable (Phase 2)

Cerebral Infarction (Phase 2)

Coronary Artery Disease (Phase 2)

Diabetic Neuropathies (Phase 2)

Dyslipidemias (Phase 3)

Hyperphosphatemia (Phase 3)

Hypertension (Phase 3)

Hypertension, Pulmonary (Phase 3)

Ischemia (Phase 2)

Kidney Diseases (Phase 3)

Polyneuropathies (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Stroke (Phase 2)

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 8